Overview

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

Status:
Not yet recruiting
Trial end date:
2027-05-26
Target enrollment:
Participant gender:
Summary
This is a prospective interventional Phase II multi center study, open label, preceded by a retrospective non-interventional period, to assess the long-term safety and efficacy of alpelisib, in pediatric and adult participants with PROS.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals